283 related articles for article (PubMed ID: 10458230)
1. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Fondurulia J; Chen MH; Kaplan I; Beard CJ; Tomaszewski JE; Renshaw AA; Wein A; Coleman CN
J Clin Oncol; 1999 Jan; 17(1):168-72. PubMed ID: 10458230
[TBL] [Abstract][Full Text] [Related]
2. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
3. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Fondurulia J; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
J Clin Oncol; 2000 Mar; 18(6):1164-72. PubMed ID: 10715284
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy.
Kupelian PA; Elshaikh M; Reddy CA; Zippe C; Klein EA
J Clin Oncol; 2002 Aug; 20(16):3376-85. PubMed ID: 12177097
[TBL] [Abstract][Full Text] [Related]
6. Optimizing patient selection for prostate monotherapy.
Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Silver B; Henry L; Hurwitz M; Kaplan I; Beard CJ; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
Mol Urol; 2000; 4(3):171-5;discussion 177. PubMed ID: 11062371
[TBL] [Abstract][Full Text] [Related]
8. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
9. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
10. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer.
D'Amico AV; Schultz D; Silver B; Henry L; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):679-84. PubMed ID: 11172949
[TBL] [Abstract][Full Text] [Related]
11. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
12. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
13. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.
D'Amico AV; Renshaw AA; Schultz D; Rocha S; Richie JP
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):847-51. PubMed ID: 10571188
[TBL] [Abstract][Full Text] [Related]
14. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.
D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Wein A; Tomaszewski JE; Coleman CN
Cancer; 1998 Jan; 82(2):334-41. PubMed ID: 9445191
[TBL] [Abstract][Full Text] [Related]
15. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Wu YH; Chen M; Art M; Tomaszewski JE; Wein A
Urology; 2000 Apr; 55(4):572-7. PubMed ID: 10736506
[TBL] [Abstract][Full Text] [Related]
16. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Renshaw AA; Tomaszewski JE; Richie JP; Wein A
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1227-33. PubMed ID: 10613317
[TBL] [Abstract][Full Text] [Related]
17. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml.
D'Amico AV; Whittington R; Kaplan I; Beard C; Jiroutek M; Malkowicz SB; Wein A; Coleman CN
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1053-8. PubMed ID: 9169812
[TBL] [Abstract][Full Text] [Related]
18. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials.
D'Amico AV; Whittington R; Malkowicz SB; Wu YH; Chen MH; Hurwitz M; Kantoff PW; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
J Clin Oncol; 2000 Sep; 18(18):3240-6. PubMed ID: 10986056
[TBL] [Abstract][Full Text] [Related]
19. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
